2026 Funding Rounds Across AI, Robotics and Genetic Engineering
The cycle records multiple capital raises and strategic deals in AI, robotics and gene‑editing, detailing amounts, investors and intended uses.
Compiled automatically from the sources listed below and checked against Hyperuranios' own capital and research data. Every figure here traces to a linked source. Factual errors reported to the contact address are corrected in the article and noted here.
Artificial Intelligence
Longevium, a Dubai‑based longevity clinic network, completed its first investment round by raising $7 million to establish a Longevity AI Research Lab at Dubai Science Park, slated to open in Q4 2026. The lab will integrate AI, biomedical research and clinical practice to develop technologies for health‑risk prediction, biological‑age measurement and lifespan extension, building on existing tools such as the Doctor Deep AI assistant and a biological‑age app. Planned research areas include digital twins, regenerative medicine, robotic diagnostics, next‑generation wearables and noble‑gas therapy. The funding was disclosed in a company statement released yesterday [1].
Antares Labs announced its public launch alongside a $7.25 million seed round that attracted participation from Fifth Wall, Base10 Partners, Bloomberg Beta and Sandwith Ventures. The company embeds AI teams directly with real‑estate owners‑operators to build custom solutions that run inside client environments, leveraging foundation models such as AWS Bedrock, OpenAI, Gemini and Anthropic while keeping proprietary data on‑premise. Its platform aims to accelerate lease‑up, improve investment decisions and predict tenant churn, delivering measurable ROI within 30 days. The round and launch were detailed in an AI PropTech news release [3].
European AI startups raised a record $23 billion in the first half of 2026, representing 55 percent of regional venture capital and a 130 percent year‑on‑year increase, according to the 2026 European AI Economy Report. Capital was heavily concentrated, with 73 percent flowing to 38 breakout companies that each secured rounds of $100 million or more, including Wayve, Isomorphic Labs, Neura Robotics and Advanced Machine Intelligence. The United Kingdom led with $12 billion (53 percent), followed by Germany ($3.5 billion) and France ($2.9 billion). The report also highlighted gender disparities in funding allocation. These figures were published in a Business Wire press release [4].
Volta Infra announced it had raised roughly $300 million across seed and Series A rounds, achieving a $2.4 billion valuation. The round was co‑led by Andreessen Horowitz and Altimeter Capital, with participation from NVIDIA and Michael Dell. In parallel, Volta secured a six‑year, approximately $10 billion compute contract with Anthropic to provide 133 megawatts of GPU capacity at a repurposed Norwegian crypto‑mining site, using NVIDIA’s Vera Rubin architecture. The company also arranged a $5 billion financing facility with asset manager Azora to help customers pre‑pay for AI chips. Details were reported in a Bloomberg‑affiliated article [7].
Robotics
Agile Robots SE acquired a majority stake in India‑based XNG Automation to strengthen its foothold in the Indian manufacturing sector. The deal combines Agile Robots’ AI‑enabled hardware, such as the Agile Hand gripper and Agile ONE humanoid robot, with XNG Automation’s system‑integration and intralogistics expertise, targeting faster adoption of intelligent production lines. While the financial terms were not disclosed, the acquisition is positioned to expand Agile Robots’ AI‑driven solutions across automotive, EV, consumer electronics and e‑commerce manufacturers in India. The transaction was reported in a company announcement [5].
Genetic Engineering
Immitra Bio, a Zürich‑based biotech, closed an oversubscribed €2.58 million pre‑seed round led by Backbone Ventures and co‑led by OCCIDENT. The funding will support preclinical development of its in‑vivo gene‑editing platform, including lead candidate IB‑003 aimed at treating an inherited form of anaemia. The capital will also expand the broader pipeline of mutation‑agnostic therapies and a digital target‑discovery platform intended to identify additional disease indications. The round and strategic focus were detailed in a Euro Startups release [2].
CRISPR Therapeutics announced the initiation of Phase I trials for two new in‑vivo gene‑editing candidates: CTX340 targeting the AGT gene in refractory hypertension, and CTX460 targeting the SERPINA1 gene in alpha‑1 antitrypsin deficiency. The updates were part of the company’s Q2 2026 earnings release, which also reported $10.2 million in revenue, a ten‑fold increase from the prior year, and a cash position of $2.36 billion. The trials join existing programs such as CTX310 for severe hypertriglyceridaemia. These developments were disclosed in a company filing [6].